Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Coward E, Waage A, Taskén K, Skånland SS(2022) Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines Front Oncol, 12, 1040730 DOI 10.3389/fonc.2022.1040730, PubMed 36523963
Zhang D, Harris HM, Chen J, Judy JT, James G, Kelly A, McIntosh J, Tenn-McClellan A, Ambing ER, Tan YS, Lu H, Gajewski S, Clifton MC, Yung S, Robbins DW, Piroozia M, Skånland SS, Gaglione EM, Mhibik M, Underbayev C, Ahn I, Sun C, Herman SEM, Noviski MA, Wiestner A(2022) -----NRX-0492 Degrades Wildtype and C481 Mutant BTK and Demonstrates in vivo Activity in CLL Patient Derived Xenografts Blood(in press) DOI 10.1182/blood.2022016934, PubMed 36375120
Flobak Å, Skånland SS, Hovig E, Taskén K, Russnes HG(2022) Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models Trends Pharmacol Sci, 43(11), 973-985 DOI 10.1016/j.tips.2022.08.009, PubMed 36163057